Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

CONCLUSION: In a real-world population we observed an undertreatment with BHAs, although patients with early BHA use had lower incidence rates of SSEs and longer SSE-FS. This finding was irrespective of type of SSE and presence of risk factors. In addition to LPD treatment, timely initiation of BHAs is recommended in bone metastatic CRPC-patients with both pain and/or opioid use and prior SSE.PMID:34848157 | DOI:10.1016/j.clgc.2021.10.008

Source: Clinical Prostate Cancer - December 1, 2021 Category: Cancer & Oncology Authors: Malou C P Kuppen Hans M Westgeest Alfons J M van den Eertwegh Reindert J A van Moorselaar Inge M van Oort Metin Tascilar Niven Mehra Jules Lavalaye Diederik M Somford Katja K H Aben Andre M Bergman Ronald de Wit A C M Fons van den Bergh Carin A Uyl- de Gr Source Type: research